Loading
Pharmacology and Obesity Treatment · Journal article
Pharmaceuticals · August 10, 2026
Early or partial results. Treat as a signal, not a conclusion.
This single-arm real-world study in 25 children found that 2-week treatment with Soagambi-tang (a herbal medicine) followed by 6-month follow-up was associated with reductions in obesity classification, body fat, and BMI percentile, alongside increases in height z-score and height percentile. However, the absence of a control arm, small sample size, and lack of blinding limit inference of causality or safety; controlled trials are required before clinical adoption can be considered.
Single-arm real-world clinical study. Children aged 7–16 years with overweight or obesity (setting, recruitment source, and detailed eligibility criteria not specified).. Intervention: Soagambi-tang (herbal medicine) administered for 2 weeks. n = 25.
Obesity classification decreased from 60.0% to 36.0% post-treatment Body fat percentage decreased from 30.24 ± 4.52% to 25.95 ± 5.44% (p < 0.0001) Fat mass significantly decreased from 15.22 ± 5.60 kg to 14.28 ± 5.77 kg (p = 0.0496)
No safety or adverse event data reported.
While the observed reductions in adiposity and concurrent increases in linear growth metrics are reassuring, the absence of a control arm precludes attribution to the herbal intervention itself. Clinicians should not adopt this treatment pending rigorous controlled trials that establish efficacy, safety profile, and superiority to existing approaches.
Single-arm, uncontrolled real-world study in 25 children with short follow-up; shows anthropometric changes and growth preservation but lacks comparator and power to establish efficacy or safety of the herbal intervention.
As stated by the source record.
Quoted from the source exactly as published.
While the observed reductions in adiposity and concurrent increases in linear growth metrics are reassuring, the absence of a control arm precludes attribution to the herbal intervention itself. Clinicians should not adopt this treatment pending rigorous controlled trials that establish efficacy, safety profile, and superiority to existing approaches.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background/Objectives: Pediatric obesity is linked to adverse metabolic outcomes and altered growth trajectories. Conventional weight-reduction strategies often raise concerns regarding potential impairment of linear growth, highlighting the need for approaches that reduce adiposity while preserving physiological development. Methods: This real-world clinical study investigated children aged 7–16 years who were administered the herbal medicine Soagambi-tang for 2 weeks, followed by a follow-up evaluation 6 months post-treatment. Anthropometric measures, body composition, and growth velocity were evaluated. Network pharmacology and molecular docking analyses were employed to investigate potential molecular mechanisms. Results: Twenty-five participants were included. After treatment, the proportion of children classified as obese decreased from 60.0% to 36.0%, and 32.0% showed improvement in weight-status category without any worsening. Body fat percentage decreased consistently among participants with available body composition data, from 30.24 ± 4.52% to 25.95 ± 5.44% (p < 0.0001), and fat mass significantly decreased from 15.22 ± 5.60 kg to 14.28 ± 5.77 kg (p = 0.0496), whereas lean body mass increased from 36.12 ± 12.08 kg to 38.89 ± 12.70 kg (p < 0.001). BMI percentile significantly decreased from 93.7 ± 3.9 to 91.2 ± 6.1 (p = 0.008), while height z-score and height percentile significantly increased from 0.57 ± 0.99 to 0.77 ± 1.07 and from 64.5 ± 25.5 to 68.6 ± 25.0, respectively (both p < 0.001). Mean annual height velocity was 7.45 ± 2.43 cm/year, and height change was positively correlated with lean body mass change (r = 0.543, p = 0.005), reflecting a meaningful upward shift in growth trajectory. In silico network pharmacology and molecular docking analyses identified key bioactive compounds in Soagambi-tang that were predicted to be associated with pathways related to pediatric obesity and puberty-associated endocrine regulation. Conclusions: These findings suggest that Soagambi-tang treatment was associated with reduced adiposity and preserved linear growth in children with overweight or obesity. Given the study design and limited sample size, controlled prospective studies are required to confirm efficacy and safety.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.